Study of FMT Combined With Nivolumab in Gastric Cancer
Status:
Withdrawn
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
This study is a single-arm, single center study. The purpose of this study is to evaluate the
efficacy and safety of FMT capsules XBI-302 combined with Nivolumab in the treatment of
anti-PD-1/L1 resistant gastric cancer.